NORWALK, Conn.--Perkin-Elmer has announced that, after a strategic review of its analytical instruments division, it will pursue selling the unit. Tony White, Perkin-Elmer's chairman, president, and CEO, said the decision was made in part to "strengthen our position as the preeminent supplier of products, information, and services to the rapidly expanding life sciences marketplace."
"With the formation of Celera Genomics and major investments in PE Biosystems, combined with the decision to sell Analytical Instruments, we have completely redefined the company," White noted. "Our objective is to accelerate the shift of genetic analysis from academia to more robust commercial applications."
In other news, the company has elected Arnold Levine, president and CEO of Rockefeller University in New York, to its board of directors. Before joining Rockefeller last year, Levine was a professor of Life Sciences at Princeton University, where he founded and guided for 12 years the molecular biology department. Previously, Levine chaired the molecular biology department at the State University of New York School of Medicine in Stony Brook. He is a member of several scientific advisory boards, including that of Perkin-Elmer's Celera Genomics business unit.